Menu
Search
|

Menu

Close
X

Sienna Biopharmaceuticals Inc SNNA.OQ (NASDAQ Stock Exchange Global Select Market)

14.63 USD
-0.37 (-2.47%)
As of 3:59 PM EST
chart
Previous Close 15.00
Open 14.99
Volume 8,558
3m Avg Volume 19,393
Today’s High 15.33
Today’s Low 14.55
52 Week High 28.95
52 Week Low 13.37
Shares Outstanding (mil) 20.54
Market Capitalization (mil) 308.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
EPS (USD)
FY17
-1.913
FY16
-1.064
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.76
Price to Sales (TTM)
vs sector
--
8.59
Price to Book (MRQ)
vs sector
3.10
5.23
Price to Cash Flow (TTM)
vs sector
--
26.13
Total Debt to Equity (MRQ)
vs sector
0.00
15.32
LT Debt to Equity (MRQ)
vs sector
0.00
11.95
Return on Investment (TTM)
vs sector
--
13.59
Return on Equity (TTM)
vs sector
--
15.20

EXECUTIVE LEADERSHIP

Frederick Beddingfield
President, Chief Executive Officer, Director, Since
Salary: --
Bonus: --
Richard Peterson
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Majed Kheir
Vice President - Operations, Since
Salary: --
Bonus: --
Susan Lundeen
Vice President - Human Resources, Since
Salary: --
Bonus: --
Robert More
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

30699 Russell Ranch Rd Ste 140
WESTLAKE VILLAGE   CA   91362-7327

Phone: +1818.6292256

Sienna Biopharmaceuticals, Inc. is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125. The Company has developed over 70 products. Its SNA-120 and SNA-125 are generated through its Topical by Design platform technology. Its SNA-120 is a Topical Tropomyosin Receptor Kinase A (TrkA) inhibitor for pruritus and psoriasis. Its SNA-125 is a Topical TrkA/Janus Kinase 3 (JAK3) Inhibitor for atopic dermatitis, psoriasis and pruritus. Its SNA-001 is a Topical Photoparticle Therapy for medical and aesthetic applications. Its SNA-001 Topical Photoparticle Therapy is used for localized and non-systemic treatment of acne. Its SNA-001 Topical Photoparticle Therapy is used for reduction of light-pigmented hair.

SPONSORED STORIES